SCHEMBL6340456

SCHEMBL6340456

CC(C)[C@H](NC(=O)OC(C)(C)C)C(=O)OCCOCn1cnc2c(=O)[nH]c(N)nc21

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.69
KMT2A Q03164 3/20 0.69
HBB P68871 2/20 0.68
MAPK1 P28482 1/20 0.68
PNP P00491 7/20 0.56
TSHR P16473 2/20 0.56
BLM P54132 2/20 0.56
USP2 O75604 1/20 0.56
EDNRA P25101 1/20 0.56
HTR2A P28223 1/20 0.56
RECQL P46063 1/20 0.56
HSD17B10 Q99714 1/20 0.56
HPRT1 P00492 6/20 0.52
POLG P54098 1/20 0.51
PDE3A Q14432 1/20 0.49
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
CYP3A4 P08684 1/20 0.48
NFKB1 P19838 1/20 0.48
VCP P55072 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14507059 0.89 MEN1 (0.75) MEN1KMT2AHBBMAPK1PNP
SCHEMBL29860149 0.87 MEN1 (0.77) MEN1KMT2AHBBMAPK1PNP
SCHEMBL14986809 0.87 MEN1 (0.77) MEN1KMT2AHBBMAPK1PNP
SCHEMBL12618101 0.86 MEN1 (0.80) MEN1KMT2AHBBMAPK1PNP
SCHEMBL13928911 0.85 MEN1 (0.65) MEN1KMT2AHBBMAPK1PNP
SCHEMBL4910722 0.85 MEN1 (0.65) MEN1KMT2AHBBMAPK1PNP
SCHEMBL3702824 0.85 MEN1 (0.49) MEN1KMT2AHBBMAPK1PNP
SCHEMBL712900 0.85 MEN1 (0.49) MEN1KMT2AHBBMAPK1PNP
SCHEMBL712899 0.85 MEN1 (0.49) MEN1KMT2AHBBMAPK1PNP
SCHEMBL3702827 0.85 MEN1 (0.49) MEN1KMT2AHBBMAPK1PNP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6849737-B2 Synthesis and purification of valacyclovir TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2005-02-01 US claimed
US-20030153757-A1 Synthesis and purification of valacyclovir TEVA PHARMACEUTICALS USA, INC. 2003-08-14 US claimed
WO-2003041647-A2 SYNTHESIS AND PURIFICATION OF VALACYCLOVIR TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2003-05-22 WO claimed
US-10836765-B2 Process for the preparation of valacyclovir AUROBINDO PHARMA LTD (IN) 2020-11-17 US disclosed
US-20190023706-A1 Process for the preparation of Valacyclovir AUROBINDO PHARMA LTD (IN) 2019-01-24 US disclosed
CN-1307177-C Synthesis and purification of valacyclovir TEVA PHARMA (IL) 2007-03-28 CN disclosed
CN-1896077-A Synthesis and purification of valacyclovir TEVA PHARMA (IL) 2007-01-17 CN disclosed
US-20050130993-A1 Synthesis and purification of valacyclovir ETINGER MARINA Y (IL) 2005-06-16 US disclosed
US-20050130993-A1 Synthesis and purification of valacyclovir ETINGER MARINA Y (IL) 2005-06-16 US disclosed
CN-1612878-A Synthesis and purification of valacyclovir TEVA PHARMA (IL) 2005-05-04 CN disclosed
US-6849737-B2 Synthesis and purification of valacyclovir TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2005-02-01 US disclosed
US-6849737-B2 Synthesis and purification of valacyclovir TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2005-02-01 US disclosed
WO-2003041647-A3 SYNTHESIS AND PURIFICATION OF VALACYCLOVIR TEVA PHARMA (IL) 2003-11-20 WO disclosed
US-20030153757-A1 Synthesis and purification of valacyclovir TEVA PHARMACEUTICALS USA, INC. 2003-08-14 US disclosed
US-20030153757-A1 Synthesis and purification of valacyclovir TEVA PHARMACEUTICALS USA, INC. 2003-08-14 US disclosed
WO-2003041647-A2 SYNTHESIS AND PURIFICATION OF VALACYCLOVIR TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2003-05-22 WO disclosed
WO-2003041647-A2 SYNTHESIS AND PURIFICATION OF VALACYCLOVIR TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2003-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130993-A1 Synthesis and purification of valacyclovir TYMP, TPMT, TYMS MEN1 961/4885KMT2A 1354/4885HBB 1982/4885
US-20030153757-A1 Synthesis and purification of valacyclovir TYMP, TPMT, TYMS MEN1 828/4885KMT2A 1512/4885HBB 1907/4885
US-20190023706-A1 Process for the preparation of Valacyclovir TYMP, SAMHD1, IMPDH1 MEN1 975/4885KMT2A 1122/4885HBB 3666/4885
US-10836765-B2 Process for the preparation of valacyclovir TYMP, SAMHD1, IMPDH1 MEN1 975/4885KMT2A 1122/4885HBB 3666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.